Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein A-I and a mutant thereof
View Patent ↗Provided is a rapamycin formulation using a recombinant high-density lipoprotein including apolipoprotein mutant, the rapamycin formulation in which solubility of rapamycin and medical use, such as aging suppression and arteriosclerosis suppression, are improved by using recombinant high-density lipoprotein including apolipoprotein A-I and its mutant V156K.
1. A rapamycin formulation comprising rapamycin and a recombinant high-density lipoprotein; wherein the rapamycin is present in an amount of 0.1 to 10 parts by weight based on a total 100 parts by weight of the recombinant high-density lipoprotein comprising an apolipoprotein (apoA-I) mutant V156K; the recombinant high-density lipoprotein comprises a mole ratio of 90 to 100 of the apoA-I mutant V156K, 1 to 10 of phospholipid, 0.1 to 2.0 of cholesterol, and 120 to 180 of sodium cholate; wherein the apoA-I mutant V156K is prepared by substitution of the amino acid valine at residue 156 with the amino acid lysine.
2. A method of preparing a rapamycin and recombinant high-density lipoprotein formulation comprising: preparing an apoA-I mutant V156K by substituting the amino acid valine at residue 156 with lysine; mixing the apoA-I mutant V156K with a phospholipid, cholesterol, and sodium cholate to prepare the recombinant high-density lipoprotein; and adding rapamycin to the recombinant high-density lipoprotein.